{"id":15070,"date":"2025-10-03T10:16:24","date_gmt":"2025-10-03T01:16:24","guid":{"rendered":"https:\/\/aireviewirush.com\/?p=15070"},"modified":"2025-10-03T10:16:24","modified_gmt":"2025-10-03T01:16:24","slug":"microbot-medical-receives-first-japanese-patent-for-liberty","status":"publish","type":"post","link":"https:\/\/aireviewirush.com\/?p=15070","title":{"rendered":"Microbot Medical receives first Japanese patent for LIBERTY"},"content":{"rendered":"


\n<\/p>\n

\n
\"Microbot<\/a><\/p>\n

Microbot Medical mentioned its aim is to take away limitations to optimum care with the LIBERTY endovascular robotic system. | Supply: Microbot Medical<\/p>\n<\/div>\n

Microbot Medical Inc., the developer of the LIBERTY Endovascular Robotic System, in the present day mentioned the Japanese Patent Workplace has granted the corporate its first patent in Japan. The patent covers the core LIBERTY expertise, similar to a compact robotic system for driving and manipulating the motion of no less than one elongate surgical software.<\/p>\n

As well as, the Hingham, Mass.-based firm<\/a> has obtained patents within the U.S., China, and Israel over the previous 90 days. It additionally earned<\/a> 510(ok) clearance from the U.S. Meals and Drug Administration (FDA) for LIBERTY<\/a> in September.<\/p>\n

\u201cOur preliminary focus is on the U.S. market. Nonetheless, sure markets, similar to Japan, characterize engaging and strategically necessary markets for the LIBERTY System,\u201d mentioned Harel Gadot, chairman, president, and CEO of Microbot. \u201cConstructing on our current FDA clearance of LIBERTY, we’re evaluating alternatives to increase into different world markets which have historically taken FDA clearance into consideration to doubtlessly expedite native approval and adoption.\u201d<\/p>\n

Based in 2010, Microbot Medical is targeted on reworking endovascular procedures by superior robotic expertise.<\/p>\n

\n
\n

Table of Contents<\/p>\n